首页> 美国卫生研究院文献>International Journal of Nanomedicine >RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life overcoming resistance and eliminating bone marrow toxicity of gemcitabine

【2h】

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life overcoming resistance and eliminating bone marrow toxicity of gemcitabine

机译：RGDV修饰的吉西他滨：一种能够延长半衰期克服耐药性并消除吉西他滨的骨髓毒性的纳米药物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundGemcitabine has been widely used as a chemotherapeutic drug. However, drug resistance, short half-life and side effects seriously decrease its chemotherapeutic efficacy.

机译：背景技术吉西他滨已被广泛用作化疗药物。然而，耐药性，半衰期短和副作用严重降低了其化学治疗功效。

著录项

期刊名称 International Journal of Nanomedicine
作者
Wenchao Liu; Yujia Mao; Xiaoyi Zhang; Yaonan Wang; Jianhui Wu; Shurui Zhao; Shiqi Peng; Ming Zhao;
展开▼
作者单位

展开▼
年(卷),期 2019(14),-1
年度 2019
页码 7263–7279
总页数 17
原文格式 PDF
正文语种
中图分类生化遗传学;生化药理学;
关键词
gemcitabine modification half-life anti-tumor tumor targeting release toxicity nano-species;

机译：吉西他滨;修饰;半衰期;抗肿瘤;肿瘤靶向;释放;毒性;纳米物种;

相似文献

外文文献
中文文献
专利

1. RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine [J] . Wenchao Liu, Yujia Mao, Xiaoyi Zhang, International Journal of Nanomedicine . 2019,第1期

机译：RGDV修饰的吉西他滨：一种能够延长半衰期，克服耐药性并消除吉西他滨的骨髓毒性的纳米药物
2. Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model [J] . DeAngelR.E., BlandoJ.M., HoganM.G., Cancer biology & therapy . 2013,第4期

机译：硬脂酰吉西他滨纳米颗粒克服了小鼠绝经后乳腺癌模型中肥胖引起的癌细胞对吉西他滨的耐药性
3. Just getting into cells is not enough: Mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression [J] . Wonganan P., Lansakara-P D.S.P., Zhu S., Journal of Controlled Release: Official Journal of the Controlled Release Society . 2013,第1a2期

机译：仅进入细胞还不够：4-（N）-硬脂酰吉西他滨固体脂质纳米颗粒克服RRM1过表达引起的吉西他滨耐药的能力的机制
4. Cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs [C] . Controlled Release Society annual meeting . 2004

机译：含有亲脂性吉西他滨前药的脂质体的细胞毒性和药代动力学
5. Enhancement of Gemcitabine and Paclitaxel Uptake and Retention in Metastatic Cancer Cells: A Novel Targeted Combination Delivery Approach to Eliminate Breast Cancer in Blood and Lymph [D] . Yu, Jesse. 2020

机译：吉西他滨和紫杉醇吸收的增强和转移性癌细胞的保留：一种小型靶向组合递送方法，消除血液和淋巴中的乳腺癌
6. Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model [O] . Rebecca E. De Angel, Jorge M. Blando, Matthew G. Hogan, 2013

机译：硬脂酰吉西他滨纳米颗粒克服了小鼠绝经后乳腺癌模型中肥胖引起的癌细胞对吉西他滨的耐药性
7. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors [O] . 南謙太朗, ミナミケンタロウ 2016

机译：核糖核苷酸还原酶是克服具有双重耐药因子的吉西他滨耐药胰腺癌细胞中吉西他滨耐药的有效靶标

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life overcoming resistance and eliminating bone marrow toxicity of gemcitabine

摘要

著录项

相似文献

相关主题

期刊订阅